J3375 Vancomycin | HCPCS Reimbursement Benchmarks

HCPCS Level II code J3375 identifies a 10 mg unit of vancomycin hydrochloride (Xellia) for parenteral administration and is distinguished as not therapeutically equivalent to J3373. This drug-specific code matters nationally because it drives billing for high-cost intravenous antibiotics used in serious gram-positive infections and affects hospital and outpatient infusion revenue, drug inventory reporting, and payer coverage determinations. Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for using vancomycin formulations, common sites of service for administration, and how the code maps to service lines for drug administration claims. The publication summarizes payer coverage patterns and benchmarking where available, highlights coding considerations tied to non-equivalent product designation, and outlines typical claim components such as drug unitization and administration service lines. It also directs readers to relevant modifiers and billing details necessary for claim adjudication. Data not available in the input is noted where specific payer policies or utilization benchmarks would otherwise be expected. The content is intended for billing managers, revenue cycle staff, pharmacists, and clinical administrators engaged in specialty drug billing and compliance.

Billing Code Overview

HCPCS Level II code J3375 represents an injectable formulation of vancomycin hydrochloride (Xellia), specified as not therapeutically equivalent to J3373, in a 10 mg unit. The code denotes a parenteral antimicrobial agent used for systemic treatment of serious gram-positive infections where vancomycin is indicated.

Service type: Drug administration — parenteral antimicrobial (intravenous infusion or injection)

Typical site of service: Hospital inpatient, hospital outpatient infusion center, physician office, or outpatient infusion center

Clinical Context

A 68-year-old hospitalized patient with a central line develops signs of a bloodstream infection: fever, rigors, hypotension, and positive Gram-positive cocci on blood culture. The infectious disease team decides to initiate intravenous vancomycin while awaiting species identification and susceptibilities. The facility uses a branded vancomycin product billed with J3375 (vancomycin hydrochloride, Xellia, not therapeutically equivalent to J3373, 10 mg) for accurate product-level billing. The typical workflow includes nursing verification of allergy history and renal function, pharmacist dose calculation and order entry, preparation of the infusion by pharmacy or an infusion nurse, and administration via peripheral or central IV access with therapeutic drug monitoring (trough or AUC-based monitoring) and subsequent dose adjustments. Documentation includes the specific drug and HCPCS code J3375, indication, dose, route, lot number for tracking, and monitoring plan.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered to any patient	When partial vial contents are discarded and must be reported per payer rules

Taxonomy Code	Specialty	Notes
`2080P0206X`	Infectious Disease Specialist	Manages selection and dosing of intravenous vancomycin for complex infections
`207RC0000X`	Clinical Pharmacist	Performs dose calculations, therapeutic drug monitoring, and medication reconciliation
`176B00000X`	Hospitalist	Manages inpatient care, orders empiric IV antibiotics such as vancomycin
`164W00000X`	Critical Care Medicine	Manages critically ill patients requiring IV vancomycin in ICU settings
`363A00000X`	Emergency Medicine	Initiates empiric IV vancomycin for suspected severe infections in the ED

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`A41.9`	Sepsis, unspecified organism	Empiric IV vancomycin is commonly started for suspected sepsis with Gram-positive coverage
`B95.61`	Methicillin resistant Staphylococcus aureus as the cause of diseases classified elsewhere	Vancomycin is a first-line agent for MRSA bloodstream and invasive infections
`J15.2`	Pneumonia due to Staphylococcus aureus	Severe staphylococcal pneumonia may be treated with IV vancomycin
`T82.7XXA`	Infection and inflammatory reaction due to other cardiac and vascular devices, implants and grafts, initial encounter	Device-related infections often require IV vancomycin for MRSA or other Gram-positive coverage
`G00.9`	Bacterial meningitis, unspecified	Empiric regimens for suspected bacterial meningitis may include vancomycin for resistant Gram-positive organisms

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when vancomycin is administered as an IV infusion and billed separately for infusion services
`36415`	Collection of venous blood by venipuncture	Performed for baseline labs and vancomycin level monitoring
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subsequent intravenous push of a new substance	May be used when additional IV bolus doses of vancomycin are given after the initial administration
`96377`	Replacement of infusion pump/therapy administration supply	Used when infusion equipment is replaced during a prolonged vancomycin infusion
`84443`	Therapeutic drug assay, vancomycin	Laboratory test used for monitoring vancomycin serum concentrations and guiding dose adjustments

OpenPayer

Summary & Overview

HCPCS J3375: Vancomycin Hydrochloride Injection, 10 mg